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Abstract
Objective—Cervical cancer screening using the human papillomavirus (HPV) test and Pap test 
together (co-testing) is an option for average-risk women ≥30 years of age. With normal co-test 
results, screening intervals can be extended. The study objective is to assess primary care provider 
practices, beliefs, facilitators and barriers to using the co-test and extending screening intervals 
among low-income women.
Method—Data were collected from 98 providers in 15 Federally Qualified Health Center 
(FQHC) clinics in Illinois between August 2009 and March 2010 using a cross-sectional survey.
Results—39% of providers reported using the co-test, and 25% would recommend a three-year 
screening interval for women with normal co-test results. Providers perceived greater 
encouragement for co-testing than for extending screening intervals with a normal co-test result. 
Barriers to extending screening intervals included concerns about patients not returning annually 
for other screening tests (77%), patient concerns about missing cancer (62%), and liability (52%).
Conclusion—Among FQHC providers in Illinois, few administered the co-test for screening and 
recommended appropriate intervals, possibly due to concerns over loss to follow-up and liability. 
Education regarding harms of too-frequent screening and false positives may be necessary to 
balance barriers to extending screening intervals.
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Introduction
Cervical cancer screening with the Papanicolaou (Pap) test has become a centerpiece of 
women's preventive healthcare, dramatically reducing cervical cancer incidence and 
mortality in the United States over the last five decades (Habbema et al., 2012). Despite 
widespread reduction in cervical cancer incidence and mortality, there are still marked 
disparities in the cervical cancer burden. Uninsured and low-income women usually are 
screened less often than recommended, and suffer disproportionate cervical cancer 
morbidity, mortality and late-stage diagnosis (Benard et al., 2008; Centers for Disease 
Control and Prevention, 2012a; Fedewa et al., 2012). Based on the role of persistent high-
risk human papillomavirus (HPV) infection in the development of cervical cancer, newer 
screening technologies have changed the landscape of screening options for women (Bosch 
et al., 2002; Centers for Disease Control and Prevention, 2012b; Munoz et al., 1992; 
Walboomers et al., 1999). In 2003 the HPV test was approved for concurrent use with the 
Pap test (known as co-testing) for women ≥ 30 years of age (US Food and Drug 
Administration, 2003). The rationale for co-testing is the increased sensitivity for detecting 
high-grade cervical pre-cancer and cancer compared with the Pap test alone (Cuzick et al., 
2008; Sherman et al., 2003). Currently, co-testing is the preferred screening approach among 
some professional organizations recommending screening guidelines (ACOG Committee on 
Practice Bulletins—Gynecology, 2012; Saslow et al., 2012). When co-test results are normal 
(normal Pap test, negative HPV test), women can wait five years until their next cervical 
cancer screening (ACOG Committee on Practice Bulletins—Gynecology, 2012; Saslow et 
al., 2012; US Preventive Services Task Force, 2012).
Despite the evidence-based recommendations for longer screening intervals, it is well 
documented that cervical cancer screening with the Pap test alone and co-test may occur 
more frequently than recommended (Holland-Barkis et al., 2006; Roland et al., 2011, 2013; 
Saraiya et al., 2010; Yabroff et al., 2009). In the average-risk population with routine access 
to care, overuse of cancer screening can cause considerable harms to patients, and undue 
costs to patients, providers, and healthcare systems (Bentley et al., 2008; Good Stewardship 
Working Group, 2011; Habbema et al., 2012; Idestrom et al., 2003; Monsonego et al., 
2011). However, no studies have examined provider cervical cancer screening practices and 
beliefs regarding co-testing and screening intervals in a low-income, underserved population 
facing barriers to care. Therefore, the Centers for Disease Control and Prevention (CDC) 
launched the Cervical Cancer (Cx3) Study to assess provider's cervical cancer screening 
knowledge, attitudes, practices, and beliefs, regarding the co-test and screening intervals to 
identify facilitators and barriers to acceptance and appropriate use of cervical cancer 
screening tests in a low-income population.
Methods
The Cx3 Study was conducted in 15 clinics associated with six Federally Qualified Health 
Centers (FQHCs) across Illinois. FQHCs were selected as study sites because they are 
safety-net providers serving individuals who disproportionately face cost and access barriers 
to healthcare. Illinois was selected as the study location based on the Illinois Breast and 
Cervical Cancer Early Detection Program's high Pap test volume, follow-up rate, and 
Roland et al. Page 2
Prev Med. Author manuscript; available in PMC 2015 August 24.
Author M
anuscript
Author M
anuscript
Author M
anuscript
Author M
anuscript
outreach activities targeting underserved women for cervical cancer screening (http://
www.cdc.gov/cancer/nbccedp/data/summaries/illinois.htm), and high incidence of cervical 
cancer in Illinois.
Data analyzed from the baseline survey were collected between August 2009 and March 
2010. Providers were eligible to participate if they personally performed Pap testing for 
routine screening. The self-administered surveys and a $50 cash incentive were sent to 
participating clinics and distributed to providers by clinic staff prior to study initiation with a 
stamped, self-addressed envelope for return. Clinic coordinators would follow-up weekly 
with non-responding providers; many were encouraged multiple times to complete the 
survey. The baseline survey was pilot tested with seven primary care providers in the 
Atlanta area to obtain an estimate of respondent burden, comments about the format, and 
appropriateness and relevance of survey questions. CDC's Institutional Review Board 
approved the study. Results are descriptive and presented as percent distributions.
Measures
The baseline provider survey was developed to assess knowledge, attitudes, beliefs and 
practices regarding cervical cancer prevention. Measures and clinical vignettes in the Cx3 
Study provider baseline survey were modeled upon national primary care provider cervical 
cancer screening practice surveys (Benard et al., 2011; Roland et al., 2011). Both provider 
and their patient's demographic data were collected, as well as Pap test and HPV test 
screening practices, attitude, and beliefs; risk management practices; and HPV vaccine 
attitudes and practices. The focus of this manuscript is to report findings regarding co-
testing and screening intervals only. Table 1 presents each measure included in this analysis, 
the corresponding question, and response options.
Results
Surveys were completed by 98 of 109 eligible providers (89.9% response rate). Most 
providers were physicians (66%), specializing in obstetrics/gynecology (53%). They 
reported an average of 8.8 years providing clinical care. Almost all providers reported 
following published guidelines for cervical cancer screening and management (94%), and 
75% reported they last participated in continuing medical education for HPV testing or 
cervical cancer screening within the previous three years (Table 2).
HPV test and screening interval practices
For patients ≥30 years of age, 39% of providers reported usually or always using the co-test 
for screening, and 91% reported usually or always using the HPV test for management after 
an ASC-US Pap test (not reported in a table or figure).
Given a clinical vignette of a 35 year old woman with a normal co-test result, over half of 
providers would recommend her next screening in one year (59%), only 25% would 
recommend next screening in three years, which was the guideline-consistent 
recommendation at the time of study. For the same woman with a normal Pap test and 
positive HPV test, 42% of providers would screen her in less than one year, and most (57%) 
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would recommend the next screening in one year, the guideline-consistent recommendation 
at the time of study (Fig. 1).
Perceived support for using the co-test and extending the interval
Providers perceived professional journals (77%), professional specialty organizations (74%), 
and national health organizations (69%) to be more encouraging of co-test use in women 
≥30 years of age than patients (34%), colleagues (50%), and administration in their practice 
(38%). Nearly one-fifth of providers (18%) perceived their administration discouraging use 
of the co-test (Table 3).
More than half of providers perceived national health organizations (57%), their 
professional specialty organizations (54%), and professional journals (54%) to encourage 
extending the screening interval to three or more years with a normal co-test result in 
women ≥30 years of age, while their perceptions of in-clinic sources of support including 
colleagues (31%), administration (17%), and patients (14%) was much lower. Providers 
perceived that nearly one-quarter of patients, colleagues and administration in their practice 
would discourage extending the screening interval (Table 3).
Beliefs about co-testing and extending the screening interval
The majority of providers stated that co-testing women ≥30 years of age was extremely or 
quite good (85%), easy (73%), and beneficial (87%). No providers reported that co-testing 
was extremely or quite bad or harmful, but 10% reported co-testing was difficult (not 
reported in a table or figure).
Many providers reported that extending the screening interval for a woman ≥30 years of age 
with a normal co-test result would be extremely or quite good (50%), with 38% stating it 
would be beneficial or easy. One-quarter reported beliefs that extending the screening 
interval with the co-test would be extremely or quite harmful (24%), difficult (23%), and bad 
(25%) (Fig. 2).
Factors considered when deciding to extend the screening interval
Nearly all providers considered medical history factors, such as history of abnormal test 
results (95%) and immune system status (90%) “a great deal” when deciding to extend the 
screening interval for a woman ≥30 years of age. Factors related to sexual history, such as 
history of a sexually transmitted infection (STI) (74%), current and lifetime number of 
sexual partners (71% and 67%, respectively) were considered important by over two-thirds 
of providers. Exposures and other behaviors, such as cigarette smoking (61%), history of 
regular Pap test screening (56%), and diethylstilbestrol (DES) exposure (54%), and patient 
not returning for future screening (53%) were moderately important (Fig. 3).
Perceived risks and benefits to extending the screening interval
Many providers reported an extended interval for a woman ≥30 years of age with a normal 
co-test result would result in the patient not visiting annually for other screening tests (77%), 
losing contact with the medical system (63%), and having increased concerns about missing 
cervical cancer (62%). Providers also felt at risk for liability if the patient's next result was 
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abnormal (52%). One benefit of extending the interval widely endorsed by providers was 
that it would help to reduce healthcare costs (71%) (Fig. 4).
Discussion
Most primary care providers believe that co-testing is good and beneficial, however, in 
practice less than half routinely used the HPV test for screening, and the majority would 
recommend next screening in one year after a normal co-test result, despite 94% of 
providers reported following published guidelines for cervical cancer screening that 
recommend triennial intervals. Poor adherence to guidelines may be due to less perceived 
support for extending the screening intervals for a normal co-test result compared to simply 
using the co-test. Specifically, providers reported less support from within the clinic 
(patients, colleagues, and administration), compared to national-level sources (professional 
organizations, professional journals, and national health organizations) for both co-testing 
and extending screening intervals, which may signal a potential need for coupling clinic-
focused with systems-level interventions.
Reported concerns about losing patients to follow-up, and personal risk of liability may 
hinder willingness to extend screening intervals. However, one commonly perceived benefit 
to extending intervals was the potential for reducing healthcare costs, a facilitator especially 
salient for public clinics such as FQHCs. While the perceived benefit in cost reduction is 
potentially helpful at a clinician- and system-level within FQHCs, patients would likely be 
less interested in messages about extending intervals that emphasized the reduction of costs 
to the clinic or public health system (Sirovich et al., 2005).
When deciding whether to extend a screening interval, factors related to a woman's medical 
and sexual history were most important to providers. Relevance of medical and sexual 
history in decision-making should diminish over time as the co-test has greater sensitivity 
for detection of high-grade cervical pre-cancer and cancer compared with the Pap test, the 
screening interval can be lengthened despite new STIs acquired in the interim, and the age 
of sexual initiation is no longer recommended as a reference for determining screening 
initiation. Immune system status, cited by 90% of providers as very important to 
determining intervals, is however, recognized by all professional organizations as an 
exception to screening guideline adherence, and should prevail as an important 
consideration. Conversely, in utero DES exposure, which increases risk for cervical cancer 
in women older than 40 years, (Smith et al., 2012) is explicitly mentioned in current 
guidelines as a risk factor that warrants more frequent screening, was noted by only 54% of 
providers.
The literature has long reported barriers to the implementation of evidence-based preventive 
health services and cancer screening at the patient-, provider-, clinic-, and health-system 
levels (Ahmad et al., 2001; Davis and Taylor-Vaisey, 1997; Jhala and Eltoum, 2007; 
Meissner et al., 2012; Tatsas et al., 2012; Wender, 1993). One-on-one education is effective 
in addressing provider cancer screening behaviors (Gorin et al., 2006; Sheinfeld et al., 2000; 
Yeager et al., 1996), however, interventions that address barriers and behavior change 
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through a multi-level, social-ecological approach are most likely to improve cancer 
prevention and care (Clauser et al., 2012; Meissner et al., 2004; Taplin et al., 2012).
This study is unique because it surveys provider practices in addition to the beliefs, attitudes, 
risks, and facilitators that drive their practice, revealing more about the behavioral 
environment within which the provider makes their clinical decisions. However, these 
findings are descriptive due to the small sample size, and therefore do not convey 
differences in responses according to provider demographics. The literature is largely 
lacking as to whether providers serving low-income populations have similar uptake of 
preventive health guidelines and procedures. As such, we do not know how these findings 
compare to FQHC providers in other states, or Illinois primary care providers not working in 
FQHCs. However, Benard et al. found providers who serve more rural, low-income, under-
insured and racially-diverse women shared low adherence to cervical cancer screening 
guidelines with providers serving the general population (Benard et al., 2011).
Primary care providers are crucial to the successful delivery of evidence-based cervical 
cancer screening. Monitoring their practices and beliefs as screening modalities and 
recommendations evolve is critical, especially among providers who serve low-income 
populations, as they may be their patient's only point of contact with the healthcare system. 
Additionally, understanding how providers adhere to cancer screening guidelines and 
general preventive health recommendations for the underserved is important to answer how 
limited resources can be used effectively, and whether extended screening guidelines 
intended for the average-risk population are appropriate for those with less frequent or 
sporadic access to care. As such, continued assessment of screening practices of FQHC 
providers across states and regions is imperative. Efforts are ongoing to increase capacity of 
FQHCs to provide clinical services, (Plescia et al., 2012) and as FQHCs receive funding to 
expand community-based, primary care services to under-insured, low-income populations, 
their providers have increasing responsibility for delivery of evidence-based cervical cancer 
screening services for women most at-risk.
Conclusion
Cervical cancer screening practices of providers serving low-income women are consistent 
with previous studies highlighting slow uptake of the co-test despite positive beliefs and 
attitudes in the utility of the co-test, and resistance to guideline-consistent screening 
intervals with normal co-test results (Benard et al., 2011; Holland-Barkis et al., 2006; 
Roland et al., 2011, 2013; Saraiya et al., 2010; Yabroff et al., 2009). Low encouragement 
from colleagues, patients and clinic administration for extending the screening intervals, and 
genuine concerns over losing patients to follow-up and being held accountable for a missed 
diagnosis may support these results. Continued intervention that targets appropriate use of 
the co-test, and the harms of too-frequent screening, and sensitizes providers to screening 
interval messages is necessary to balance the abundance of perceived harms to extending 
screening intervals.
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Fig. 1. 
Primary care provider recommended screening intervals based on the co-test result for a 
woman 35 years of age (n = 97), 2009–2010. (Study was conducted in 15 Federally 
Qualified Health Center clinics in Illinois, USA, 2009–2010). HPV = human 
papillomavirus.
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Fig. 2. 
Primary care provider beliefs about extending the screening interval to 3 years for a woman 
≥30 years of age with a normal co-test result, 2009–2010. (Study was conducted in 15 
Federally Qualified Health Center clinics in Illinois, USA, 2009–2010). Total n for each 
measure: beneficial-harmful n = 94; easy-difficult n = 95; good-bad n = 95. Survey 
questions: Deciding to extend the cervical cancer screening interval to 3 or more years 
because a woman ≥30 years of age had received a normal Pap result and negative HPV test 
would be… 1) good versus bad; 2) easy versus difficult; and 3) beneficial versus harmful.
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Fig. 3. 
Factors considered important to primary care providers when deciding to extend the 
screening interval for a women ≥30 years of age1 (n = 97), 2009–2010. (Study was 
conducted in 15 Federally Qualified Health Center clinics in Illinois, USA, 2009–
2010). 1No distinction made as to whether the Pap test or the HPV and Pap test (co-test) 
would be used to screen.
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Fig. 4. 
Primary care provider perceived risks and benefits to extending the screening interval for a 
30 year old woman with a normal co-test result, 2009–2010. (Study was conducted in 15 
Federally Qualified Health Center clinics in Illinois, USA, 2009–2010). The total n for all 
measures = 97, except for “help reduce healthcare costs”, and “increase patient concerns 
about missing cervical cancer” where n = 96.
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Table 1
Survey measures, baseline Cx3 Study provider survey administered at 15 Federally Qualified Health Center 
clinics in Illinois, USA (2009–2010).
Measure Question Response options
HPV test practices For your female patients ≥30 years of age, how often do you use 
HPV testing:
1) With the Pap test for routine cervical cancer screening; and
2) as a follow-up test for an atypical squamous cells of 
undetermined significance (ASC-US) Pap test?
Never; sometimes; half the time; 
usually; or always
Screening interval practices For a woman 35 years of age, indicate the next cervical cancer 
screening interval you would be most likely to recommend for her 
next test given:
1) A normal Pap this visit, negative HPV test this visit; and
2) normal Pap this visit, positive HPV test this visit.
<1 year; 1 year; 2 years; 3 years; or 
>3 yearsa
Perceived support for using the 
co-test
Please indicate the extent to which you feel that the following 
individuals or entities encourage or discourage you to conduct HPV 
testing along with Pap testing for routine screening in women ≥30 
years of age: 1) patients; 2) colleagues; 3) administration in 
practice; 4) professional health organizations; 5) professional 
specialty organizations; and 6) professional journals
Strongly discourage; discourage; 
neither; encourage; or strongly 
encourageb
Perceived support for extending 
screening intervals
Please indicate the extent to which the following individuals or 
entities encourage or discourage you to extend the screening 
interval to 3 years between tests for women ≥30 years of age with a 
normal Pap result and a negative HPV test: 1) patients; 2) 
colleagues; 3) administration in practice; 4) professional health 
organizations; 5) professional specialty organizations; and 6) 
professional journals
Strongly discourage; discourage; 
neither; encourage; or strongly 
encourage b
Beliefs about co-testing Conducting HPV testing along with Pap testing for routine 
screening in women ≥30 years of age is… 1) Good versus bad; 2) 
easy versus difficult; and 3) beneficial versus harmful.
1) Extremely good; quite good; 
neither; quite bad; or extremely 
badc; 2) extremely easy; quite 
easy; neither; quite difficult; or 
extremely difficultd; and 3) 
extremely beneficial; quite 
beneficial; neither; quite harmful; 
or extremely harmfule.
Beliefs about screening intervals Deciding to extend the cervical cancer screening interval to 3 or 
more years because a woman ≥30 years of age had received a 
normal Pap result and negative HPV test would be… 1) good 
versus bad; 2) easy versus difficult; and 3) beneficial versus 
harmful.
1) Extremely good; quite good; 
neither; quite bad; or extremely 
bad; 2) extremely easy; quite easy; 
neither; quite difficult; or 
extremely difficult; 3) extremely 
beneficial; quite beneficial; neither; 
quite harmful; or extremely 
harmfule.
Factors considered when 
extending a woman's screening 
interval (with a Pap test alone or 
the co-test)
To what extent do you consider the following factors in deciding 
whether or not to extend the cervical cancer screening interval for 
women ≥30 years of age? 19 statements related to medical history, 
sexual history, exposures, behaviors, and socio-demographics.
Not at all; some; or a great deal
Perceived risks and benefits to 
extending the screening interval
For a woman ≥30 years of age with a normal Pap result and a 
negative HPV test, please indicate the extent to which you agree or 
disagree with the following statements about extending the 
screening interval to three or more years between tests. 10 
statements related to perceived risk and benefits of extending the 
screening interval.
Strongly disagree; disagree; 
neither; agree; or strongly agree f
aAt the time of survey (2009–2010), screening guidelines recommended a three-year screening interval with a normal co-test result, (ACOG 
Committee on Practice Bulletins—Gynecology, 2009; Saslow et al., 2002) and a one-year screening interval with a normal Pap test, positive HPV 
test (Apgar et al., 2009).
bStrongly discourage and discourage results were collapsed together, and strongly encourage and encourage results were collapsed together.
c
Extremely good and quite good results were collapsed together, and extremely bad and quite bad results were collapsed together.
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d
Extremely easy and quite easy results were collapsed together, and extremely difficult and quite difficult results were collapsed together.
e
Extremely beneficial and quite beneficial results were collapsed together, and extremely harmful and quite harmful results were collapsed 
together.
fStrongly disagree and disagree results were collapsed together, and strongly agree and agree results were collapsed together.
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Table 2
Personal characteristics of providers who completed the baseline survey for the Cx3 Study (n = 98). (Study 
was conducted in 15 Federally Qualified Health Center clinics in Illinois, USA, 2009–2010).
Number of
providers
Percent or
mean ± SD
Age (years) 98 41.3 ± 11.4
Location of clinic
  Chicago 68 69
  Outside Chicago 30 31
Gender
  Male 23 23
Female 75 77
Hispanic or Latino origin
  Hispanic 6 6
  Non-Hispanic 92 94
Race or racial heritage (check all that apply)
  White 51 55
  Black or African American 19 20
  Asian 23 25
  Native Hawaiian/Pacific Islander 1 1
  American Indian/Alaska Native 1 1
Type of clinician
  Physician 65 66
  Nurse practitioner 20 20
  Certified nurse midwife 6 6
  Physician's assistant 7 7
Primary clinical specialty
  Family medicine 35 36
  Internal medicine 8 8
  Obstetrics/gynecology 52 53
  Pediatrics 1 1
Years providing clinical care 98 8.8 ± 9.5
Primary care outpatient settings
  1 68 71
  2 19 20
  ≥3 9 9
Hours/week providing direct patient care 97 37.5 ± 13.9
Professional time spent in various activities (% per month)
  Primary care, mean percent 96 66.9 ± 34.4
  Subspecialty care, mean percent 96 20.0 ± 31.9
  Research, mean percent 96 1.3 ± 3.4
  Teaching, mean percent 96 6.6 ± 13.5
  Administration, mean percent 96 5.4 ± 10.9
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Number of
providers
Percent or
mean ± SD
  Other, mean percent 95 0.8 ± 5.3
Follow published guidelines for cervical cancer screening and management
  Yes 92 94
  No 3 3
  Don't know 3 3
Clinic implemented guidelines for cervical cancer screening and management
  Yes 63 66
  No 20 21
  Don't know 13 13
Affiliation with a medical school, adjunct clinical, or other faculty appointment
  Yes 26 27
  No 71 73
Last time participated in a CMEa on HPVb testing or screening
  Within the past 3 years 73 75
  3–6 years ago 7 7
  >6 years ago 4 4
  Never 13 14
aCME = continuing medical education.
b
HPV = human papillomavirus.
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